Multiple defects in energy metabolism in Alzheimer's disease

Current Drug Targets

Volumn 11, Issue 10, 2010, Pages 1193-1206

  Ferreira, I L ^a   Resende, R ^a   Ferreiro, E ^a   Rego, A C ^a,b   Pereira, C F ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alzheimer's disease; Calcium; Endoplasmic reticulum; Glucose metabolism; Glutamate receptors; Mitochondria

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUTAMATE RECEPTOR; TRICARBOXYLIC ACID;

ALZHEIMER DISEASE; ARTICLE; CALCIUM HOMEOSTASIS; ENDOPLASMIC RETICULUM; ENERGY METABOLISM; GLUCOSE METABOLISM; HUMAN; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; NEUROIMAGING; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS;

EID: 77957994659     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450111007011193     Document Type: Article

References (198)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-1403.
2. Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 2006; 3: 437-148.
3. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004; 62: 925-131.
4. Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 2006; 9: 101-115.
5. Scheff SW, Price DA, Schmitt FA, et al. Synaptic alterations in CA1 in mild Alzheimer's disease and mild cognitive impairment. Neurology 2007; 68:1501-8.
6. Hof PR, Giannakopoulos P, Vickers JC, et al. The morphologic and neurochemical basis of dementia: aging, hierarchical patterns of lesion distribution and vulnerable neuronal phenotype. Rev Neurosci 1995; 6: 97-124.
7. Mann DM. Pyramidal nerve cell loss in Alzheimer's disease. Neurodegeneration 1996; 5: 423-427.
8. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008; 1147: 180-195.
9. Moreira PI, Cardoso SM, Pereira CM, et al. Mitochondria as a therapeutic target in Alzheimer's disease and diabetes. CNS Neurol Disord Drug Targets 2009; 8: 492-511.
10. Milionis HJ, Florentin M, Giannopoulos S. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? CNS Spectr 2008; 13: 606-613.
11. S Roriz-Filho J, Sá-Roriz TM, Rosset I, et al. (Pre) diabetes, brain aging, and cognition. Biochim Biophys Acta 2009; 1792: 432-443.
12. Zhang T, Pan BS, Zhao B, et al. Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-secretase activation and beta-amyloid generation in rat brains. Neuroscience 2009; 161: 1045-1056.
13. Pasinetti GM, Zhao Z, Qin W, et al. Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications. Interdiscip Top Gerontol 2007; 35: 159-175.
14. Halagappa VK, Guo Z, Pearson M, et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2007; 26: 212-220.
15. Qin W, Zhao W, Ho L, et al. Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. Ann N Y Acad Sci 2008; 1147: 335-347.
16. McNay EC. Insulin and ghrelin: peripheral hormones modulating memory and hippocampal function. Curr Opin Pharmacol 2007; 7: 628-632.
17. Freude S, Schilbach K, Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 2009; 6: 213-223.
18. Pedersen WA, McMillan PJ, Kulstad JJ, et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199: 265-273.
19. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta amyloid in early AD. Neurology 2008; 70: 440-448.
20. de Leon MJ, Ferris SH, George AE, et al. Positron emission tomographic studies of aging and Alzheimer disease. Am J Neuroradiol 1983; 4: 568-571.
21. Ogawa M, Fukuyama H, Ouchi Y, et al. Altered energy metabolism in Alzheimer's disease. J Neurol Sci 1996; 139: 78-82.
22. Haense C, Buerger K, Kalbe E, et al. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. Eur J Neurol 2008; 15: 1155-1162.
23. Marshall GA, Monserratt L, Harwood D, et al. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007; 64: 1015-1020.
24. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 2005; 102: 8299-8302.
25. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005; 64: 1860-1867.
26. Schöll M, Almkvist O, Axelman K, et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging 2009. [Epub ahead of print].
27. Pihlajamäki M, Sperling RA. Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals. Behav Neurol 2009; 21: 77-91.
28. DeCarli C, Atack JR, Ball MJ, et al. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration 1992; 1: 113-121.
29. Ceravolo R, Borghetti D, Kiferle L, et al. CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. Brain Res Bull 2008; 76: 80-84.
30. Kalaria RN, Gravina SA, Schmidley JW, et al. The glucose transporter of the human brain and blood-brain barrier. Ann Neurol 1988; 24: 757-764.
31. Liu Y, Liu F, Iqbal K, et al. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 2008; 582: 359-364.
32. Bigl M, Apelt J, Eschrich K, et al. Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. J Neural Transm 2003; 110: 77-94.
33. Mazzola JL, Sirover MA. Subcellular alteration of glyceraldehyde-3-phosphate dehydrogenase in Alzheimer's disease fibroblasts. J Neurosci Res 2003; 71: 279-285.
34. Cumming RC, Schubert D. Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease. FASEB J 2005; 19: 2060-2062.
35. Pereira C, Santos MS, Oliveira C. Involvement of oxidative stress on the impairment of energy metabolism induced by Abeta peptides on PC12 cells: protection by antioxidants. Neurobiol Dis 1999; 6: 209-219.
36. Butterfield DA, Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 2009; 111: 915-933.
37. Schubert D, Soucek T, Blouw B. The induction of HIF-1 reduces astrocyte activation by amyloid beta peptide. Eur J Neurosci 2009; 29: 1323-1334.
38. Vingtdeux V, Dreses-Werringloer U, Zhao H, et al. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci 2008; 9 Suppl 2: S6.
39. Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-563.
40. Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010; 285: 9100-9113.
41. Palmer AM. The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. J Neural Transm 1999; 106: 317-128.
42. Russell RL, Siedlak SL, Raina AK, et al. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 1999; 370: 236-239.
43. Gibbs ME, Gibbs Z, Hertz L. Rescue of Abeta(1-42)-induced memory impairment in day-old chick by facilitation of astrocytic oxidative metabolism: implications for Alzheimer's disease. J Neurochem 2009; 109 (Suppl 1): 230-236.
44. Lin AP, Shic F, Enriquez C, et al. Reduced glutamate neurotransmission in patients with Alzheimer's disease-an in vivo (13)C magnetic resonance spectroscopy study. MAGMA 2003; 16: 29-42.
45. Bubber P, Haroutunian V, Fisch G, et al. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 2005; 57: 695-703.
46. Ferrer I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2009; 41: 425-431.
47. Shi Q, Xu H, Kleinman WA, et al. Novel functions of the alpha-ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease. Biochim Biophys Acta 2008; 1782: 229-238.
48. Brooks WM, Lynch PJ, Ingle CC, et al. Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res 2007; 1127: 127-135.
49. Liang WS, Reiman EM, Valla J, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA 2008; 105: 4441-4446.
50. Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 2008; 5: 470-480.
51. Kashiwaya Y, Takeshima T, Mori N, et al. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 2000; 97: 5440-5444.
52. Studzinski CM, MacKay WA, Beckett TL, et al. Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. Brain Res 2008; 1226: 209-217.
53. Reger MA, Henderson ST, Hale C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004; 25: 311-314.
54. Bosetti F, Brizzi F, Barogi S, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 2002; 23:371-6.
55. Cardoso SM, Proença MT, Santos S, et al. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 2004a; 25: 105-110.
56. Valla J, Schneider L, Niedzielko T, et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006; 6: 323-330.
57. Baloyannis SJ. Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis 2006; 9: 119-126.
58. Davis RE, Miller S, Hermstadt C, et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1997; 94: 4526-4531.
59. Trimmer PA, Borland MK. Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid Redox Signal 2005; 7: 1101-1109.
60. Pamplona R, Dalfó E, Ayala V, et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 2005; 280: 21522-21530.
61. Terni B, Boada J, Portero-Otin M, et al. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer's disease pathology. Brain Pathol 2010; 20: 222-223.
62. Rhein V, Song X, Wiesner A, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009; 106: 20057-20062.
63. Pavlov PF, Petersen CH, Glaser E, et al. Mitochondrial accumulation of APP and Abeta: Significance for Alzheimer disease pathogenesis. J Cell Mol Med 2009. [Epub ahead of print].
64. Anandatheerthavarada HK, Biswas G, Robin MA, et al. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 2003; 161: 41-54.
65. Caspersen C, Wang N, Yao J, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 2005; 19: 2040-2041.
66. Hansson Petersen CA, Alikhani N, Behbahani H, et al. The amyloid betapeptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 2008; 105: 13145-13150.
67. Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links A to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304: 448-152.
68. Takuma K, Yao J, Huang J, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 2005; 19: 597-598.
69. Chen X, Yan SD. Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease. IUBMB Life 2006; 58: 686-694.
70. Du H, Yan SS. Mitochondrial permeability transition pore in Alzheimer's disease: Cyclophilin D and amyloid beta. Biochim Biophys Acta 2010; 180: 198-204.
71. Crouch PJ, Blake R, Duce JA, et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 2005; 25: 672-679.
72. Hansson CA, Frykman S, Farmery MR, et al. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 2004; 279: 51654-51660.
73. Leissring MA, Farris W, Wu X, et al. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J 2004; 383: 439-146.
74. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 2009; 218: 286-292.
75. Cardoso SM, Santos S, Swerdlow RH, et al. Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J 2001; 15: 1439-1441.
76. Canevari L, Clark JB, Bates TE. beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 1999; 457: 131-134.
77. Moreira PI, Santos MS, Moreno A, et al. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep 2001; 21: 789-800.
78. Moreira PI, Santos MS, Moreno AM, et al. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes 2003; 52: 1449-1456.
79. Moreira PI, Santos MS, Sena C, et al. CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol 2005; 196: 112-119.
80. Pereira C, Santos MS, Oliveira C. Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. Neuro Rep 1998; 9: 1749-1755.
81. Rhein V, Baysang G, Rao S, et al. Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 2009; 29: 1063-1071.
82. Keil U, Bonert A, Marques CA, et al. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 2004; 279: 50310-50320.
83. Hauptmann S, Scherping I, Dröse S, et al. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 2009; 30: 1574-1586.
84. Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106: 14670-14675.
85. Fattoretti P, Balietti M, Casoli T, et al. Decreased Numeric Density of Succinic Dehydrogenase-Positive Mitochondria in CA1 Pyramidal Neurons of 3xTg-AD Mice. Rejuvenation Res 2010; 13: 144-147.
86. Yang TT, Hsu CT, Kuo YM. Cell-derived soluble oligomers of human amyloid-beta peptides disturb cellular homeostasis and induce apoptosis in primary hippocampal neurons. J Neural Transm 2009; 116: 1561-1569.
87. Eckert A, Hauptmann S, Scherping I, et al. Oligomeric and fibrillar species of beta-amyloid (Abeta42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med 2008; 86: 1255-1267.
88. Colell A, Fernández A, Fernández-Checa JC. Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease. J Bioenerg Biomembr 2009; 41: 417-423.
89. Fernández A, Llacuna L, Fernández-Checa JC, et al. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J Neurosci 2009; 29: 6394-6405.
90. Li F, Calingasan NY, Yu F, et al. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 2004; 89: 1308-1312.
91. Sompol P, Ittarat W, Tangpong J, et al. A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience 2008; 153: 120-130.
92. Massaad CA, Washington TM, Pautler RG, et al. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106:13576-13581.
93. Dumont M, Wille E, Stack C, et al. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 2009; 23: 2459-2466.
94. David DC, Hauptmann S, Scherping I, et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 2005; 280: 23802-23814.
95. Quintanilla RA, Matthews-Roberson TA, Dolan PJ, et al. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J Biol Chem 2009; 284:18754-18766.
96. Cantó C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab. 2009; 20: 325-331.
97. Qin W, Yang T, Ho L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006; 281: 21745-21754.
98. Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-40374.
99. Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006; 96: 305-313.
100. Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 121-126.
101. Luchsinger JA, Tang MX, Shea S, et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003 60:203-208.
102. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 2006; 1762: 256-265.
103. Doody RS. Dimebon as a potential therapy for Alzheimer's disease. CNS Spectr 2009; 14: 14-16
104. Bachurin SO, Shevtsova EP, Kireeva EG, et al. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003; 993.
105. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement and mitophagy-in neurodegenerative diseases. Hum Mol Gene 2009; 18: 169-176.
106. Wang X, Su B, Zheng L, et al. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 2009; 109 (Suppl 1): 153-159.
107. Wang X, Su B, Siedlak SL, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 2008; 105:19318-19323.
108. Wang X, Su B, Fujioka H, et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol 2008; 173: 470-482.
109. Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009; 29: 9090-9103.
110. Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009; 324: 102-105.
111. Barsoum MJ, Yuan H, Gerencser AA, et al. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J 2006; 25: 3900-3911.
112. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008; 31: 454-463.
113. Giacomello M, Drago I, Pizzo P, et al. Mitochondrial Ca2+ as a key regulator of cell life and death. Cell Death Differ 2007; 14: 1267-1274.
114. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 2002; 3: 862-872.
115. Mattson MP, Liu D. Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem Biophys Res Commun 2003; 304: 539-549.
116. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002; 5: 405-414.
117. Stanika RI, Pivovarova NB, Brantner CA, et al. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci USA 2009; 106: 9854-9859.
118. Zhou M, Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci 2006; 26: 2956-2963.
119. Liu Y, Wong TP, Aarts M, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 2007; 27: 2846-2857.
120. Rizzuto R, Brini M, Murgia M, et al. Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science 1993; 262: 744-747.
121. Macaskill AF, Rinholm JE, Twelvetrees AE, et al. Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. Neuron 2009; 61: 541-555.
122. Deshpande A, Mina E, Glabe C, et al. Different conformations of amyloid induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006; 26: 6011-6018.
123. Mattson MP, Guo Q, Furukawa K, et al. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J Neurochem 1998; 70: 1-14.
124. Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodege-neration in a prodromal stage of Alzheimer's disease. J Neurosci Res 2010; 88: 469-477.
125. Almeida CG, Tampellini D, Takahashi RH, et al. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 2005; 20: 187-198.
126. Shankar GM, Bloodgood BL, Townsend M, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-2875.
127. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008; 451: 720-724.
128. Small DH, Gasperini R, Vincent AJ, et al. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2009; 16: 225-233.
129. Parameshwaran K, Dhanasekaran M, Suppiramaniam V. Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 2008; 210: 7-13.
130. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
131. De Felice FG, Velasco PT, Lambert MP, et al. Abeta oligomers induce neuronal oxidative stress through an N-Methyl-D-aspartate Receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282: 11590-11601.
132. Alberdi E, Sánchez-Gómez MV, Cavaliere F, et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010; 47: 264-272.
133. Dinamarca MC, Colombres M, Cerpa W, et al. Beta-amyloid oligomers affect the structure and function of the postsynaptic region: role of the Wnt signaling pathway. Neurodegener Dis 2008; 5: 149-152.
134. Deshpande A, Kawai H, Metherate R, et al. A role for synaptic zinc in activity-dependent abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 2009; 29: 4004-4015.
135. Hu NW, Klyubin I, Anwy R, et al. GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci USA 2009; 106: 20504-20509.
136. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-1058.
137. Johansson S, Radesater AC, Cowburn RF, et al. Modelling of amyloid beta-peptide induced lesions using roller-drum incubation of hippocampal slice cultures from neonatal rats. Exp Brain Res 2006; 168: 11-24.
138. Goto Y, Niidome T, Akaike A, et al. Amyloid beta peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. Biochem Biophys Res Commun 2006; 351: 259-265.
139. Kelly BL, Ferreira A. Beta-amyloid-induced dynamin 1 degradation is mediated by NMDA receptors in hippocampal neurons. J Biol Chem 2006; 281: 28079-28089.
140. Song S, Lee H, Kam TI, et al. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicity. J Cell Biol 2008; 182: 675-684.
141. Furukawa K, Barger SW, Blalock EM, et al. Activation of K+ channels and suppression of neuronal activity by secreted β-amyloid-precursor protein. Nature 1996; 379: 74-8.
142. Leissring MA, Murphy MP, Mead TR, et al. A physiologic signaling role for the γsecretase-derived intracellular fragment of APP. Proc Natl Acad Sci USA 2002; 99: 4697-4702.
143. Andrews ZB, Diano S, Horvath TL. Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat Rev Neurosci 2005; 6: 829-840.
144. Sullivan PG, Springer JE, Hall ED, et al. Mitochondrial uncoupling as a therapeutic target following neuronal injury. J Bioenerg Biomembr 2004; 36: 353-356.
145. Liu D, Chan SL, de Souza-Pinto NC, et al. Mitochondrial UCP4 mediates an adaptive shift in energy metabolism and increases the resistance of neurons to metabolic and oxidative stress. Neuromolecular Med 2006; 8: 389-414.
146. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006; 9: 167-181.
147. Berridge MJ. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 2002; 32: 235-249.
148. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115: 2656-2664.
149. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7: 1013-1030.
150. Hoozemans JJM, Veerhuis R, Van Haastert ES, et al. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol 2005; 110: 165-172.
151. Hoozemans JJ, van Haastert ES, Nijholt DA, et al. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol 2009; 174: 1241-1251.
152. Selwood SP, Parvathy S, Cordell B, et al. Gene expression profile of the PDAPP mouse model for Alzheimer's disease with and without Apolipoprotein E. Neurobiol Aging 2009; 30: 574-590.
153. Song S, Lee H, Kam TI, et al. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicity. J Cell Biol 2008; 182: 675-684.
154. Ling ZQ, Tian Q, Wang L, et al. Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin. J Alzheimers Dis 2009; 16: 287-300.
155. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 2000; 403: 98-103.
156. Ghribi O, Herman MM, Pramoonjago P, et al. GDNF regulates the A beta-induced endoplasmic reticulum stress response in rabbit hippocampus by inhibiting the activation of gadd 153 and the JNK and ERK kinases. Neurobiol Dis 2004; 16: 417-427.
157. Hitomi J, Katayama T, Eguchi Y, et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol 2004; 165: 347-356.
158. Heinitz K, Beck M, Schliebs R, et al. Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56. B5. G4 cells. J Neurochem 2006; 98: 1930-1945.
159. Chafekar SM, Zwart R, Veerhuis R, et al. Increased Abeta1-42 production sensitizes neuroblastoma cells for ER stress toxicity. Curr Alzheimer Res 2008; 5: 469-474.
160. Lai CS, Preisler J, Baum L, et al. Low molecular weight Abeta induces collapse of endoplasmic reticulum. Mol Cell Neurosci 2009; 41:32-43.
161. Liu J, Zhu W, Qin H, et al. NMR studies reveal a novel mode for hFADD to bind with the unstructured hRTN3 which initiates the ER-stress activated apoptosis. Biochem Biophys Res Commun 2009; 383: 433-439.
162. Nishitsuji K, Tomiyama T, Ishibashi K, et al. The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol 2009; 174: 957-969.
163. Takahashi K, Niidome T, Akaike A, et al. Amyloid precursor protein promotes endoplasmic reticulum stress-induced cell death via C/EBP homologous protein-mediated pathway. J Neurochem 2009; 109: 1324-1337.
164. Ferreiro E, Resende R, Costa R, et al. An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol Dis 2006; 23: 669-678.
165. Resende R, Ferreiro E, Pereira C, et al. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 2008; 155: 725-737.
166. Resende R, Ferreiro E, Pereira C, et al. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J Neurosci Res 2008; 86: 2091-2099.
167. Stutzmann GE, LaFerla FM, Parker I. Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci 2003; 23: 758-765.
168. Stutzmann GE, Caccamo A, LaFerla FM, et al. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci 2004; 24: 508-513.
169. Zhang C, Wu B, Beglopoulos V, et al. Presenilins are essential for regulating neurotransmitter release. Nature 2009; 460: 632-636.
170. Copanaki E, Schurmann T, Eckert A, et al. The amyloid precursor protein potentiates CHOP induction and cell death in response to ER Ca2+depletion. Biochim Biophys Acta 2007; 1773: 157-165.
171. Ferreiro E, Oliveira CR, Pereira, et al. Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. J Neurosci Res 2004; 76: 872-880.
172. Supnet C, Grant J, Kong H, et al. Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. J Biol Chem 2006; 281: 38440-38447.
173. Smith IF, Hitt B, Green KN, et al. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem 2005; 94: 1711-1718.
174. Stutzmann GE, Smith I, Caccamo A, et al. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci 2006; 26: 5180-5189.
175. Chakroborty S, Goussakov I, Miller MB, et al. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci 2009; 29: 9458-9470.
176. Giorgi C, De Stefani D, Bononi A, et al. Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int J Biochem Cell Biol 2009; 41:1817-1827.
177. Pinton P, Ferrari D, Magalhaes P, et al. Reduced loading of intracellular Ca2+ stores and downregulation of capacitative Ca2+ influx in Bcl-2-overexpressing cells. J Cell Biol 2000; 148: 857-862.
178. Bernardi P, Petronilli V, Di Lisa F, et al. A mitochondrial perspective on cell death. Trends Biochem Sci 2001; 26: 112-117.
179. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001; 3: 255-263.
180. Deniaud A, Sharaf el dein O, Maillier E, et al. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 2008; 27: 285-299.
181. Foyouzi-Youssefi R, Arnaudeau S, Borner C, et al. Bcl-2 decreases the free Ca2+ concentration within the endoplasmic reticulum. Proc Natl Acad Sci USA 2000; 97: 5723-5728.
182. Nutt LK, Chandra J, Pataer A, et al. Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 2002a; 277: 20301-20308.
183. Nutt LK, Pataer A, Pahler J, et al. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem 2002b; 277: 9219-9225.
184. Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK Regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003; 300: 135-139.
185. Szalai G, Krishnamurthy R, Hajnoczky G. Apoptosis driven by IP(3)-linked mitochondrial calcium signals. EMBO J 1999; 18: 6349-6361.
186. Szado T, Vanderheyden V, Parys JB, et al. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc Natl Acad Sci USA 2008; 105: 2427-2432.
187. Boehning D, Patterson RL, Sedaghat L, et al. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol 2003; 5: 1051-1061.
188. Boehning D, Patterson RL, Snyder SH. Apoptosis and calcium: new roles for cytochrome c and inositol 1,4,5-trisphosphate. Cell Cycle 2004; 3: 252-254.
189. Wang S, El-Deiry WS. Cytochrome c: a crosslink between the mitochondria and the endoplasmic reticulum in calcium-dependent apoptosis. Cancer Biol Ther 2004; 3: 44-46.
190. Area-Gomez E, de Groof AJ, Boldogh I, et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol 2009; 175: 1810-1816.
191. Perreault S, Bousquet O, Lauzon M, et al. Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau. J Neuropathol Exp Neurol 2009; 68: 503-514.
192. Ferreiro E, Oliveira CR, Pereira CM. The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway. Neurobiol Dis 2008; 30: 331-342.
193. Costa RO, Ferreiro E, Cardoso SM, et al. Endoplasmic reticulum stress-mediated apoptotic pathway induced by Aβ1-40 peptide requires the presence of functional mitochondria. J Alzheimer Dis 2010; 20: 625-636.
194. Csordás G, Hajnóczky G. SR/ER-mitochondrial local communication: calcium and ROS. Biochim Biophys Acta 2009; 1787:1352-1362.
195. Racay P, Kaplan P, Lehotsky J, et al. Rabbit brain endoplasmic reticulum membranes as target for free radicals. Changes in Ca2+-transport and protection by stobadine. Biochem Mol Biol Int 1995; 36: 569-577.
196. Huang H, Zhang H, Ou H, et al. α-Keto-β-methyl-n-valeric acid diminishes reactive oxygen species and alters endoplasmic reticulum Ca2+ stores. Free Radical Biol Med 2004; 37: 1779-1789.
197. Marciniak SJ, Yun CY, Oyadomari S, et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004; 18: 3066-3077.
198. Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 2005; 13: 159-163.